Atosiban SUN: Uses, Dosage & Side Effects

What Is Atosiban SUN and What Is It Used For?

Atosiban SUN belongs to a class of medications known as oxytocin receptor antagonists. The active substance, atosiban, is a synthetic peptide structurally related to the naturally occurring hormone oxytocin. However, instead of stimulating uterine contractions like oxytocin does, atosiban competes with oxytocin for binding sites on the myometrial (uterine muscle) cells, effectively blocking the hormone's contractile action. This competitive antagonism is the foundation of its therapeutic effect in preterm labor management.

When atosiban binds to the oxytocin receptors on the smooth muscle cells of the uterus, it prevents the oxytocin-mediated increase in intracellular calcium concentration. Under normal circumstances, oxytocin binding triggers a signaling cascade that releases calcium from intracellular stores and promotes calcium entry through membrane channels, leading to actin-myosin interactions and, ultimately, uterine muscle contraction. By blocking this process, atosiban effectively reduces both the frequency and the force of uterine contractions without eliminating them entirely.

In addition to its activity at the oxytocin receptor, atosiban also exhibits some affinity for vasopressin V1a receptors. Vasopressin (antidiuretic hormone, ADH) can also stimulate uterine contractions through V1a receptors, so the dual antagonism may contribute to the overall tocolytic effect. However, the clinical significance of the vasopressin receptor antagonism relative to the oxytocin receptor blockade is thought to be modest in the context of tocolysis.

Atosiban SUN is indicated for use in adult pregnant women presenting with symptoms of preterm labor from 24 completed weeks up to 33 completed weeks of gestation. The primary clinical goal of tocolysis with atosiban is not to permanently halt preterm labor but rather to gain sufficient time for two critical interventions: the administration of antenatal corticosteroids (such as betamethasone or dexamethasone) to accelerate fetal lung maturation, and the transfer of the mother to a tertiary center equipped with a neonatal intensive care unit (NICU) if needed. Antenatal corticosteroids take approximately 24 to 48 hours to exert their maximum beneficial effect on fetal lung surfactant production, and this time window is precisely what tocolysis with atosiban is designed to provide.

Preterm birth, defined as birth before 37 completed weeks of gestation, is the leading cause of neonatal morbidity and mortality worldwide. According to the World Health Organization (WHO), an estimated 13.4 million babies were born preterm in 2020, and complications related to preterm birth are the leading cause of death among children under the age of five. While many tocolytic agents have been developed over the decades, including beta-adrenergic agonists (such as ritodrine and terbutaline), calcium channel blockers (nifedipine), magnesium sulfate, and prostaglandin synthetase inhibitors (indomethacin), atosiban is distinguished by its relatively favorable maternal side-effect profile compared to beta-agonists and its specificity for the uterine smooth muscle.

Atosiban was first authorized in the European Union in 2000 under the brand name TRACTOCILE. Since then, several generic versions have been approved, including Atosiban SUN, manufactured by Sun Pharmaceutical Industries Europe B.V. (Hoofddorp, Netherlands), and Atosiban EVER Pharma. These products are therapeutically equivalent and contain the same active substance at the same concentrations. Atosiban is not approved by the U.S. Food and Drug Administration (FDA), as the pivotal clinical trial submitted for FDA review did not demonstrate a statistically significant benefit over placebo in the primary endpoint. Nevertheless, it remains widely used in Europe, Asia, and many other regions and is included in several international guidelines as a first-line or recommended tocolytic option.

What Should You Know Before Taking Atosiban SUN?

Contraindications

Atosiban SUN must not be used in certain clinical situations where the risks of delaying delivery outweigh the potential benefits of prolonging the pregnancy. These absolute contraindications are based on established obstetric principles and clinical trial safety data. It is essential that the prescribing physician performs a thorough assessment before initiating treatment.

These contraindications are designed to ensure that atosiban is only used in situations where delaying delivery is both safe and clinically beneficial. In conditions such as severe preeclampsia, eclampsia, or significant placental abruption, the immediate delivery of the baby is often the definitive treatment, and delaying delivery with a tocolytic could place both the mother and baby at greater risk. Similarly, in cases of intrauterine infection, continuing the pregnancy allows the infection to progress and can lead to life-threatening sepsis for both mother and baby.

Warnings and Precautions

Even in the absence of absolute contraindications, there are several situations in which atosiban must be used with particular caution and increased clinical surveillance. Your doctor, midwife, or nurse will carefully weigh the potential benefits against the risks in each of these scenarios.

An important consideration following treatment with atosiban is the potential for uterine atony after delivery. Because atosiban blocks oxytocin receptors, the uterus may be less responsive to endogenous oxytocin during the postpartum period, which could theoretically increase the risk of postpartum hemorrhage. Clinicians should be prepared to manage this potential complication with appropriate uterotonic agents if needed.

If contractions resume after an initial course of treatment, atosiban therapy may be repeated up to three additional times during the same pregnancy. However, more than four total treatment cycles should not be administered. The decision to retreat should be based on a reassessment of the clinical situation, including gestational age, cervical dilatation, fetal well-being, and the presence or absence of new contraindications.

Pregnancy and Breastfeeding

Atosiban SUN is inherently a medication used during pregnancy, as its sole indication is the management of preterm labor in pregnant women. It has been studied in clinical trials involving pregnant women from 24 to 33 weeks of gestation, and the available evidence does not indicate any harmful effects on the fetus or the newborn. However, treatment should always be initiated and monitored in a hospital setting where both maternal and fetal conditions can be closely observed.

If you are breastfeeding an older child while receiving treatment with atosiban, you should stop breastfeeding during the treatment period. Small amounts of atosiban may be excreted in breast milk, and as a precautionary measure, breastfeeding should be suspended until treatment is completed. This precaution is standard for many medications used during acute clinical situations in hospital settings.

Children and Adolescents

There is no clinical experience with the use of atosiban in pregnant women under the age of 18 years. Preterm labor can occur in adolescent pregnancies, but the safety and efficacy of atosiban in this population have not been specifically studied. Any decision to use atosiban in an adolescent patient must be made on a case-by-case basis by the treating physician, considering the potential benefits and the lack of specific data.

How Does Atosiban SUN Interact with Other Drugs?

Because atosiban is a peptide that is metabolized by plasma peptidases rather than by hepatic cytochrome P450 enzymes, it has a low potential for classical pharmacokinetic drug interactions. It does not inhibit or induce any of the major CYP450 enzymes. Nevertheless, several potential pharmacodynamic interactions warrant clinical attention.

It is important that you inform your doctor, midwife, or pharmacist about all medications you are currently taking, have recently taken, or might take. This includes prescription medications, over-the-counter drugs, herbal supplements, and vitamins. The clinical team managing your preterm labor will integrate this information into their treatment decisions.

Although formal drug interaction studies are limited, the clinical experience with atosiban over more than two decades of use in Europe has not revealed any unexpected or serious drug interactions. The primary concern remains pharmacodynamic in nature, particularly the risk of excessive tocolysis or cardiovascular complications when multiple agents affecting uterine contractility or blood pressure are used simultaneously. In clinical practice, atosiban is frequently co-administered with antenatal corticosteroids without any issues, and this combination forms the cornerstone of preterm labor management in many European centers.

What Is the Correct Dosage of Atosiban SUN?

Atosiban SUN is exclusively administered in a hospital setting by qualified healthcare professionals (doctors, midwives, or nurses). The medication is given intravenously (directly into a vein), and patients are not expected to self-administer this drug. Before administration, healthcare staff will verify that the solution is clear, colorless, and free from visible particles.

Adult Dosage (Standard Three-Step Protocol)

The standard atosiban dosing protocol follows a well-established three-step regimen designed to rapidly achieve therapeutic plasma levels and then maintain them for sufficient time to allow antenatal corticosteroids to take effect.

The total duration of a single treatment cycle must not exceed 48 hours. During the treatment, your contractions and your baby's heart rate will be continuously or intermittently monitored using cardiotocography (CTG). This monitoring allows the clinical team to assess the effectiveness of the tocolysis and to detect any signs of fetal distress early.

Retreatment

If uterine contractions resume after a completed course of atosiban, treatment may be started again following the same three-step protocol. The medication may be administered for up to three additional treatment cycles during the same pregnancy (for a maximum of four total cycles). The decision to retreat is based on a renewed clinical assessment, including reassessment of gestational age, cervical status, fetal well-being, and the absence of any newly developed contraindications. More than four treatment cycles should not be used during a single pregnancy due to limited safety data beyond this threshold.

Special Populations

Hepatic impairment: No specific dose adjustments are recommended for patients with hepatic impairment, but atosiban should be used with caution in this population due to limited clinical data. Close clinical monitoring is advised.

Renal impairment: Similarly, no formal dose adjustments have been established for patients with renal impairment. Since a fraction of atosiban is eliminated via the kidneys, reduced renal function may theoretically result in higher plasma concentrations. Close monitoring is recommended.

Overdose

Clinical experience with atosiban overdose is very limited. There have been few reported cases of overdose, and no specific symptoms of toxicity have been consistently associated with supratherapeutic doses. Based on the pharmacological profile, potential effects of overdose could include excessive uterine relaxation, nausea, vomiting, headache, and hypotension. Treatment of overdose is supportive, with management of symptoms as they arise. There is no specific antidote for atosiban. In the event of a suspected overdose, discontinue the infusion immediately and provide supportive care, including monitoring of uterine contractility, blood pressure, and fetal heart rate.

What Are the Side Effects of Atosiban SUN?

Like all medicines, Atosiban SUN can cause side effects, although not everybody experiences them. The side effects observed with atosiban are generally mild and affect the mother only. Extensive clinical trial data and post-marketing surveillance have not identified any specific adverse effects on the unborn baby or the newborn attributable to atosiban. The safety profile of atosiban is considered favorable compared to older tocolytic agents such as beta-adrenergic agonists, which can cause significant maternal cardiovascular side effects including tachycardia, palpitations, chest pain, and pulmonary oedema.

The following side effects have been reported with the use of atosiban, categorized by their frequency of occurrence:

The hyperglycemia observed during atosiban treatment is typically mild and transient, resolving after discontinuation of the infusion. It is thought to be related to the pharmacological mechanism of atosiban and is generally not clinically significant in most patients. However, in women with gestational diabetes or pre-existing diabetes mellitus, blood glucose levels should be monitored more closely during atosiban treatment.

The risk of pulmonary oedema is a recognized but rare complication that deserves particular attention. This risk appears to be increased in women with multiple pregnancies (twins or higher-order multiples) and in those receiving concurrent tocolytic therapy or intravenous fluid loading. Clinicians should monitor fluid balance carefully and be vigilant for symptoms such as dyspnoea (shortness of breath), chest tightness, persistent cough, or decreased oxygen saturation. If pulmonary oedema is suspected, atosiban should be discontinued immediately and appropriate supportive treatment initiated.

How Should You Store Atosiban SUN?

Proper storage of Atosiban SUN is essential to ensure the medication remains safe and effective. As a hospital-administered medication, storage is primarily the responsibility of the pharmacy and clinical staff. However, understanding the storage requirements provides important context about the product.

• Temperature: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.
• Light protection: Keep in the original packaging to protect from light. Atosiban is sensitive to light degradation.
• Once opened: The product must be used immediately after opening the vial. Any unused solution should be discarded.
• Visual inspection: Before administration, the solution must be visually inspected for particulate matter and discoloration. Only a clear, colorless solution free from particles should be used.
• Expiry date: Do not use after the expiry date (EXP) printed on the label. The expiry date refers to the last day of the stated month.
• Keep out of reach of children: Store where children cannot access it.
• Disposal: Do not dispose of unused medicines via household waste or wastewater. Ask your pharmacist about proper disposal methods to help protect the environment.

In clinical practice, the pharmacy department will maintain the cold chain for atosiban and deliver it to the labor ward as needed. Once the infusion has been prepared, it should be used promptly. The European Medicines Agency SmPC specifies that the prepared infusion solution should be used within 24 hours when stored below 25°C, although institutional policies may require shorter use-by times for prepared admixtures. Always follow your hospital's local pharmacy guidelines.

What Does Atosiban SUN Contain?

Understanding the full composition of any medication is important, particularly for patients with known allergies or sensitivities to specific excipients. Atosiban SUN is formulated with a minimal number of inactive ingredients, reflecting its nature as an injectable pharmaceutical product.

Active Substance

The active substance is atosiban, present as atosiban acetate. Each vial of Atosiban SUN 6.75 mg/0.9 ml solution for injection contains atosiban acetate equivalent to 6.75 mg of atosiban in 0.9 ml of solution. This formulation is used for the initial bolus injection (Step 1 of the dosing protocol). The concentrate for solution for infusion (37.5 mg/5 ml) contains atosiban acetate equivalent to 37.5 mg of atosiban in 5 ml. This formulation is diluted and used for the continuous infusion steps (Steps 2 and 3).

Inactive Ingredients (Excipients)

• Mannitol: A sugar alcohol used as an osmotic agent to create an isotonic solution suitable for intravenous administration. Mannitol helps maintain the stability and tonicity of the formulation.
• Hydrochloric acid 1M: Used for pH adjustment to ensure the solution has an appropriate pH for intravenous injection (approximately pH 4.5). Proper pH is essential for both product stability and patient comfort during injection.
• Water for injections: The pharmaceutical-grade solvent that forms the base of the injectable solution. It meets strict purity standards required for intravenous products.

Physical Appearance

Atosiban SUN 6.75 mg/0.9 ml solution for injection is a clear, colorless solution without visible particles. It is supplied in glass vials. Each pack contains one vial with 0.9 ml of solution. If the solution appears cloudy, discolored, or contains particles, it must not be used.

Other Available Brands

Atosiban is available from multiple manufacturers under different brand names, all containing the same active substance at equivalent concentrations. The following products are available in various markets:

• TRACTOCILE (Ferring Pharmaceuticals) – the original reference product, first authorized in the EU in 2000
• Atosiban EVER Pharma (EVER Pharma) – generic version authorized in the EU
• Atosiban SUN (Sun Pharmaceutical Industries Europe B.V.) – generic version, the subject of this article

All approved atosiban products have demonstrated bioequivalence to the reference product and are considered therapeutically interchangeable. The choice of which brand to use is typically determined by hospital procurement and pharmacy decisions. Patients can be reassured that switching between authorized atosiban products does not affect the safety or efficacy of treatment.